Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study

Caroline Robert, Michal Kiciński, Caroline Dutriaux, Émilie Routier, Anne-Sophie Govaerts, Emanuel Bührer, Eve‐Marie Neidhardt, Xavier Durando, Barouyr Baroudjian, Philippe Saïag, Caroline Gaudy‐Marqueste, Paolo A Ascierto, Ana Arance, Michelangelo Russillo, Jean‐Luc Perrot, Laurent Mortier, F. Aubin, Stéphane Dalle, Florent Grange, Eva Muñoz‐Couselo, Sorilla Mary-Prey, Mona Amini‐Adlé, Sandrine Mansard, Célèste Lebbé, Elisa Funck‐Brentano, S. Monestier, Alexander Eggermont, Felix Boakye Oppong, Leen Wijnen, Bastian Schilling, M. Mandala, Paul Lorigan, Alexander C. J. van Akkooi